- In March 2025, Biohaven Pharmaceuticals announced upcoming topline data from two Phase 3 clinical trials for troriluzole (a novel glutamate modulator) in OCD, expected in the first half and second half of 2025, respectively. Troriluzole aims to address the glutamate system, a new avenue for OCD treatment. This highlights ongoing efforts to introduce new mechanisms of action beyond traditional SSRIs.
- In August 2023, Talkiatry partnered with NOCD to integrate psychiatric care with specialized Exposure and Response Prevention (ERP) therapy, revolutionizing OCD treatment through combined services. This collaboration aims to enhance patient outcomes by improving accessibility and streamlining OCD care, particularly for online therapy
- In June 2021, Teva Pharmaceutical Industries Ltd. launched generic SOOLANTRA (ivermectin) Cream for rosacea in the U.S., significantly expanding its dermatology portfolio and global footprint. This strategic move mirrors the diversification and expansion efforts observed within the OCD drugs market, where pharmaceutical companies continuously aim to broaden treatment options and address varied patient needs, thereby influencing market competitiveness and fostering innovation
- In April 2021, Lundbeck and Otsuka Pharmaceutical Co., Ltd. continued their Phase 3 trials for brexpiprazole as an adjunctive treatment for agitation in patients with Alzheimer’s dementia. The successful completion of such trials can lead to the launch of new products, significantly impacting company revenues and market dynamics. This parallels the ongoing pursuit of innovative treatments and expanded indications within the OCD drugs market, which constantly influences therapeutic options and market landscapes.
- In April 2021, Biohaven Pharmaceuticals initiated a pivotal Phase 3 clinical trial for troriluzole as an adjunctive therapy for obsessive-compulsive disorder (OCD). This significant undertaking underscores the pharmaceutical industry's persistent efforts to develop innovative and potentially more effective treatments for OCD, reflecting the dynamic landscape of the OCD drugs market, which is continuously driven by the pursuit of novel therapeutic options and improved patient outcomes, particularly for those with treatment-resistant forms
